Prevención del riesgo cardiovascular

Un repaso a las novedades científicas relacionadas con la prevención de los factores de riesgo y la implantación de un estilo de vida cardiosaludable que fueron presentadas en el ESC Congress'08.

Título sesión	Título	Ponente
Fallacies from clinical trials	Hypertension.	Ruilope L M (Madrid, ES)
Fallacies from clinical trials	Dyslipidemia.	Barter P J (Sydney, AU)
Preventive cardiology in primary care - EUROASPIRE III	Design of EUROASPIRE III in primary care.	Wood D A (London, GB)
Preventive cardiology in primary care - EUROASPIRE III	Risk factor and therapeutic results.	Keil U (Muenster, DE)
Obese children - a growing target for life style intervention	Vascular dysfunction in obese children.	Erbs S (Leipzig, DE)
Obese children - a growing target for life style intervention	Nutrition - impact of interventional programmes.	Riccardi G (Naples, IT)
How to improve blood pressure control?	Scope of the problem.	Jones D W (Jackson, US)
How to improve blood pressure control?	Better antihypertensive drugs?	Kjeldsen S E (Oslo, NO)
How to improve blood pressure control?	The polypill?	Clement D L (Gent, BE)
Hot Line II	Coronary Artery Revascularisation in Diabetes. The CARDia trial.	Kapur A (London, GB)
Hot Line II	Coronary Artery Revascularisation in Diabetes. The CARDia trial - Discussant.	Fuster V (New York, US)
Rheumatic heart disease impact in developing world	Cardiovascular disease - a worldwide perspective.	Sheikh S A (Lahore, PK)
Rheumatic heart disease impact in developing world	What is the social and economic dimension of the problem?	Mayosi B M (Cape Town, ZA)
Rheumatic heart disease impact in developing world	Is prophylaxis reasonably achievable and is it a priority?	Halees Z Al (Riyadh, SA)
Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention	Assessing the metabolic syndrome: does it matter in the evaluation of global cardiovascular disease risk?	Haffner S M (San Antonio, US)
Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention	Abdominal obesity, metabolic syndrome and cardiovascular disease risk: the interventional cardiologist's perspective.	Steg P G (Paris Cedex 18, FR)
Targeting abdominal obesity and the metabolic syndrome to optimally manage global cardiovascular disease risk: exploring opportunities for prevention	Treating hypertension in the metabolic syndrome: is there a preferred drug?	Ruilope L M (Madrid, ES)
Clinical Trial Update II	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation - results of the ADVANCE study.	Patel A (Sydney, AU)
Clinical Trial Update II	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation - results of the ADVANCE study. - Discussant.	Le Heuzey J-Y (Paris, FR)
Clinical Trial Update II	Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients - analysis from the EUROPA study.	Bertrand M E (Lambersart, FR)
Clinical Trial Update II	Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients - analysis from the EUROPA study - Discussant.	Sever P S (London, GB)
Clinical Trial Update III	Blood Pressure Analyses from 25595 patients (from 25620 randomised) during the ONTARGET Trial: Reflections on Current Guidelines - Discussant.	Ruschitzka F T (Zurich, CH)
Clinical Trial Update III	The Euro CardioVascular Healthcare Index 2008. - Discussant.	Breithardt G (Munster, DE)
Clinical Trial Update III	EUROASPIRE III: Lifestyle, risk factor and therapeutic menagement in people at high risk of developing cardiovascular disease from 12 European regions.	Wood D A (London, GB)
Clinical Trial Update III	EUROASPIRE III: Lifestyle, risk factor and therapeutic menagement in people at high risk of developing cardiovascular disease from 12 European regions. - Discussant.	Ryden L (Stockholm, SE)
Highlight Session	Hypertension and risk factors.	Schunkert H (Lubeck, DE)
Highlight Session	Prevention.	Perk J (Oskarshamn, SE)
When and where is surgery worthwhile and cost-effective?	Rheumatic heart disease impact in developing world	Antunes MJ (Coimbra, PT)

Cardiología hoy | Blog

Guías clínicas

Agenda SEC

CardioPODCAST

Cursos SEC

Másteres y Posgrados

Formación SEC 2025

CardioTV

Prevención del riesgo cardiovascular

Actualidad

Revista Española de Cardiología

REC: Interventional Cardiology

REC: CardioClinics

Socios estratégicos